Towards third generation matrix metalloproteinase inhibitors for cancer therapy.
The failure of matrix metalloproteinase (MMP) inhibitor drug clinical trials in cancer was partly due to the inadvertent inhibition of MMP antitargets that counterbalanced the benefits of MMP target inhibition. We explore how MMP inhibitor drugs might be developed to achieve potent selectivity for validated MMP targets yet therapeutically spare MMP antitargets that are critical in host protection.
Overall
C M
CM
CBCRA Program in Breast Cancer Metastasis, Department of Oral Biological & Medical Sciences, The UBC Centre for Blood Research, University of British Columbia, Vancouver, BC, Canada V6T 1Z3. chris.overall@ubc.ca
Kleifeld
O
O
D000595:Amino Acid Sequence; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004791:Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D061965:Matrix Metalloproteinase Inhibitors; D020782:Matrix Metalloproteinases / Q000378:metabolism*; D008969:Molecular Sequence Data; D009369:Neoplasms / Q000188:drug therapy / Q000201:enzymology; D010447:Peptide Hydrolases / Q000378:metabolism; D013379:Substrate Specificity
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D061965:Matrix Metalloproteinase Inhibitors; D010447:Peptide Hydrolases; D020782:Matrix Metalloproteinases